Skip to content
value.today

Calithera Biosciences, Inc.

Formerly Protein Activation Therapeutics, Inc.

Total raised
$63 M
5 rounds on record
Latest round
$16 M
Jul 2014
First round on record
Jun 2010
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Calithera Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2014$16 MNo. 5$10 to $50 million

Calithera Biosciences, Inc.: Raise no. 5, Jul 2014

Investors in this round

19 investors had bought by the notice of Jul 31, 2014: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Calithera Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $30 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series D Preferred Stock as convertible into shares of Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Susan M. Molineaux · Executive Officer, Director
  • William M. Waddill · Executive Officer
  • Deepa M. Pakianathan · Director
  • Jean M. George · Director
  • Jonathan M. Drachman · Director
  • Ralph E. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Susan M. Molineaux, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 31, 2014. Read the notice at the SEC.

equitySEC
Oct 2013$27 MNo. 4$10 to $50 million

Calithera Biosciences, Inc.: Raise no. 4, Oct 2013

Investors in this round

17 investors had bought by the notice of Oct 25, 2013: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Calithera Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $35 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Susan Molineaux · Executive Officer, Director
  • Deepika Pakianathan · Director
  • Jean George · Director
  • Ralph Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Susan Molineaux, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 25, 2013. Read the notice at the SEC.

equitySEC
Dec 2012$2 MNo. 3$2 to $10 million

Calithera Biosciences, Inc.: Raise no. 3, Dec 2012

Investors in this round

4 investors had bought by the notice of Dec 31, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Calithera Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $11 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and Issuance of Series C Preferred Stock as convertible into shares of Common Stock
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Susan M. Molineaux · Executive Officer, Director
  • Deepa M. Pakianathan · Director
  • Jean M. George · Director
  • Ralph M. Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Danielle Naftulin, Assistant Secretary. Source: SEC Form D, newest notice filed Dec 31, 2012. Read the notice at the SEC.

equitySEC
Nov 2011$8 MNo. 2$2 to $10 million

Calithera Biosciences, Inc.: Raise no. 2, Nov 2011

Investors in this round

6 investors had bought by the notice of May 31, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Calithera Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $32 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series B Preferred Stock as convertible into shares of common stock
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Susan Molineaux · Executive Officer, Director
  • Deepa Pakianathan · Director
  • Jean George · Director
  • Laurence Lasky · Director
  • Ralph Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Danielle Naftulin Reed, Assistant Secretary. Source: SEC Form D and 1 amendment, newest notice filed May 31, 2012. Read the notice at the SEC.

equitySEC
Jun 2010$10 MNo. 1$10 to $50 million

Calithera Biosciences, Inc.: Raise no. 1, Jun 2010

Investors in this round

7 investors had bought by the notice of Jul 16, 2010: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Calithera Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $40 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series a Preferred Stock as convertible into shares of common stock
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Susan Molineaux · Executive Officer, Director
  • James Wells · Director
  • Jean George · Director
  • Laurence Lasky · Director
  • Ralph Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Danielle Naftulin Reed, Assistant Secretary. Source: SEC Form D, newest notice filed Jul 16, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Calithera Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2014).

    SEC Form D · Jul 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2014

That is all the official record says: Calithera Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Calithera Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Advanced Technology Ventures VIII LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ATV Associates VIII, L.L.C.Othernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Delphi BioInvestments VIII LPFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Delphi Management Partners VIII, L.L.C.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Delphi Ventures VIII LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Millennium Pharmaceuticals IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Morgenthaler Venture Partners IX LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Takeda Pharmaceutical Co LTDCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Calithera Biosciences, Inc.
NameRoleNamed in
Susan M. MolineauxExecutive officerJul 2014
William M. WaddillExecutive officerJul 2014
Susan MolineauxExecutive officerOct 2013
Deepa M. PakianathanDirectorJul 2014
Jean M. GeorgeDirectorJul 2014
Jonathan M. DrachmanDirectorJul 2014
Ralph E. ChristoffersenDirectorJul 2014
Susan M. MolineauxDirectorJul 2014
Deepika PakianathanDirectorOct 2013
Jean GeorgeDirectorOct 2013
Ralph ChristoffersenDirectorOct 2013
Susan MolineauxDirectorOct 2013
Ralph M. ChristoffersenDirectorDec 2012
Deepa PakianathanDirectorMay 2012
Laurence LaskyDirectorMay 2012
James WellsDirectorJul 2010